Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Cannabis Act topic
No spam. Unsubscribe anytime.
Senate debates SB 73, adopts amendments and 'circles' substitute for further consideration
Summary
Senator Madsen presented SB 73 as a tightly regulated Medical Cannabis Act focused on the neediest patients; floor amendments addressed zoning, employee protections, compassionate-use board membership, dosing, and costs before the Senate 'circled' the substitute for later consideration.
Get email alerts on the Medical Cannabis Act topic
No spam. Unsubscribe anytime.
Senator Madsen, sponsor of Senate Bill 73, described the measure as a carefully constructed, tightly regulated medical-cannabis program intended to provide access for the "neediest among us" while avoiding recreational legalization. "This is not a bill for recreational use of cannabis in any way," Madsen said, arguing the proposal cherry-picks regulatory controls from other states to limit unintended consequences.
On the floor the sponsor offered a sequence of amendments (1–7) addressing municipal zoning preemption, protections for state and local employees, the composition and authority of a compassionate-use board, inspection protocols and patient cost controls. A central policy tension concerned whether to allow unprocessed plant material (the "whole plant") as an option to keep costs low for patients; amendment 7, which would have preserved whole-plant access as a low-cost option, failed on the floor.
Other amendments passed, including changes expanding the compassionate-use appeals process, clarifying inspection cadence, and modifying local zoning authority; senators debated whether protections for state employees would remain and whether local municipalities could exclude dispensaries. Sponsor Madsen emphasized patient testimony in the gallery and repeatedly invoked the urgency of providing relief to children, veterans and other patients who travel out of state to obtain cannabis products.
After back-and-forth questions about dosing, the 'entourage effect,' and pharmacological alternatives such as Marinol, the Senate ultimately voted to "circle" the substitute for SB 73 so it can be taken up again; the sponsor indicated willingness to continue negotiating changes before further readings.
Ending: With amendments adopted and others rejected, the Senate circled the substitute for SB 73 and will continue consideration at a later floor session.
